HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13), an innovative commercial-stage biopharmaceutical company focused on oncology and immunological therapies, has announced that China's updated National Reimbursement Drug List (NRDL), effective 1 January 2027, will include expanded coverage for two of its marketed medicines: ELUNATE® (fruquintinib) and ORPATHYS® (savolitinib). The update follows a contract renewal with China's National Healthcare Security Administration (NHSA) and introduces new indications for both drugs alongside renewals of existing ones. Investors may be watching closely given that NRDL inclusion directly influences patient access, drug pricing, and commercial uptake across China's vast insured population.

Key Points

  • HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13)
  • Updated NRDL, effective 1 January 2027, adds new indications for ELUNATE® and ORPATHYS® following NHSA contract renewal
  • ELUNATE® gains a new renal cell carcinoma combination indication; ORPATHYS® gains a new NSCLC combination indication and renews an existing one; SULANDA® retains continued coverage
  • Investors should watch how the expanded indications affect commercial uptake across China, where 1.33 billion people held basic medical insurance as of end-2025

ELUNATE® Added for Renal Cell Carcinoma in Combination with Sintilimab

Fruquintinib, a selective oral inhibitor of all three VEGFR subtypes (VEGFR-1, -2 and -3), has been newly listed under the updated NRDL for patients with locally advanced or metastatic renal cell carcinoma who have failed prior VEGFR tyrosine kinase inhibitor therapy and have not received PD-1 or PD-L1 inhibitor therapy in the first-line setting. The new indication is in combination with sintilimab injection. ELUNATE® is co-developed and co-commercialised in China by HUTCHMED and Eli Lilly and Company, while Takeda holds the exclusive worldwide licence outside mainland China, Hong Kong and Macau, marketing the drug as FRUZAQLA®.

ORPATHYS® Secures New NSCLC Combination Listing and Renewal for MET Exon 14 Skipping Indication

Savolitinib, an oral and highly selective MET tyrosine kinase inhibitor jointly developed by AstraZeneca and HUTCHMED and commercialised by AstraZeneca as ORPATHYS®, has secured two separate NRDL updates. It has been newly included for locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification, following disease progression on EGFR-TKI therapy, in combination with osimertinib. Additionally, its listing for adult patients with locally advanced or metastatic NSCLC harbouring a MET exon 14 skipping alteration has been renewed, maintaining commercial access for that patient population.

China's 1.33 Billion-Person Insurance Base Underpins NRDL Commercial Significance

The announcement states that as of end-2025, approximately 1.33 billion people in China held basic medical insurance coverage, representing around 95% of the entire population. NRDL inclusion, which is renewed every two years, is a critical commercial gateway for pharmaceutical companies operating in China, as it determines whether a drug is reimbursable under the national scheme. Category B medicines, including novel oncology drugs such as those involved in this update, require varying degrees of patient copayment depending on provincial or insurance scheme arrangements, which remains a key commercial variable for HUTCHMED.

SULANDA® Retains Coverage as HUTCHMED Holds Worldwide Surufatinib Rights

SULANDA® (surufatinib), HUTCHMED's novel oral angio-immuno kinase inhibitor targeting VEGFRs, FGFR and CSF-1R, retains its existing NRDL coverage under current multi-year agreements. Unlike ELUNATE® and ORPATHYS®, surufatinib is marketed solely by HUTCHMED in China, and the company retains all rights to the drug worldwide. This distinction means that any commercial benefit from SULANDA®'s continued NRDL listing accrues entirely to HUTCHMED, without revenue-sharing obligations to a commercial partner, though the announcement does not disclose sales figures or financial projections for any of the three products.